PL2561368T3 - Kompozycje i sposoby do przewidywania wrażliwości i oporności na lek oraz progresji choroby - Google Patents
Kompozycje i sposoby do przewidywania wrażliwości i oporności na lek oraz progresji chorobyInfo
- Publication number
- PL2561368T3 PL2561368T3 PL11772505T PL11772505T PL2561368T3 PL 2561368 T3 PL2561368 T3 PL 2561368T3 PL 11772505 T PL11772505 T PL 11772505T PL 11772505 T PL11772505 T PL 11772505T PL 2561368 T3 PL2561368 T3 PL 2561368T3
- Authority
- PL
- Poland
- Prior art keywords
- prediction
- compositions
- resistance
- methods
- disease progression
- Prior art date
Links
- 206010061818 Disease progression Diseases 0.000 title 1
- 230000005750 disease progression Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000035945 sensitivity Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32571710P | 2010-04-19 | 2010-04-19 | |
| US35649510P | 2010-06-18 | 2010-06-18 | |
| US42117810P | 2010-12-08 | 2010-12-08 | |
| US201161443146P | 2011-02-15 | 2011-02-15 | |
| PCT/US2011/032935 WO2011133477A2 (en) | 2010-04-19 | 2011-04-18 | Compositions and methods for prediction of drug sensitivity, resistance, and disease progression |
| EP11772505.1A EP2561368B1 (en) | 2010-04-19 | 2011-04-18 | Compositions and methods for prediction of drug sensitivity, resistance, and disease progression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL2561368T4 PL2561368T4 (pl) | 2018-03-30 |
| PL2561368T3 true PL2561368T3 (pl) | 2018-03-30 |
Family
ID=44834747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11772505T PL2561368T3 (pl) | 2010-04-19 | 2011-04-18 | Kompozycje i sposoby do przewidywania wrażliwości i oporności na lek oraz progresji choroby |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9766249B2 (enExample) |
| EP (1) | EP2561368B1 (enExample) |
| JP (2) | JP6158078B2 (enExample) |
| KR (1) | KR101977875B1 (enExample) |
| CN (2) | CN102947706B (enExample) |
| AU (1) | AU2011242990B2 (enExample) |
| CA (1) | CA2795362C (enExample) |
| ES (1) | ES2650674T3 (enExample) |
| HK (1) | HK1258688A1 (enExample) |
| PL (1) | PL2561368T3 (enExample) |
| SG (1) | SG184507A1 (enExample) |
| WO (1) | WO2011133477A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2294216A4 (en) | 2008-05-14 | 2011-11-23 | Dermtech Int | DIAGNOSIS OF MELANOMA AND SOLAR LENTIGO BY ANALYSIS OF NUCLEIC ACIDS |
| CA2767616A1 (en) | 2009-07-09 | 2011-01-13 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
| WO2014145705A2 (en) | 2013-03-15 | 2014-09-18 | Battelle Memorial Institute | Progression analytics system |
| CN104152397A (zh) * | 2013-05-13 | 2014-11-19 | 复旦大学 | 一种致敏动物的脾细胞模型及其在药物筛选中的用途 |
| GB201314485D0 (en) * | 2013-08-13 | 2013-09-25 | Electrophoretics Ltd | Materials and methods relating to pancreatic cancer |
| TW201601753A (zh) * | 2013-09-30 | 2016-01-16 | 第一三共股份有限公司 | 蛋白質生物標記及其用途 |
| WO2022187196A1 (en) * | 2021-03-02 | 2022-09-09 | Dermtech, Inc. | Predicting therapeutic response |
| US11578373B2 (en) | 2019-03-26 | 2023-02-14 | Dermtech, Inc. | Gene classifiers and uses thereof in skin cancers |
| US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| US11104951B2 (en) | 2014-05-22 | 2021-08-31 | The Scripps Research Institute | Molecular signatures for distinguishing liver transplant rejections or injuries |
| CN104745700A (zh) * | 2015-03-27 | 2015-07-01 | 南京医科大学 | 一种食管癌相关甲基化生物标志物及应用 |
| CN107922504B (zh) * | 2015-07-07 | 2021-07-30 | 豪夫迈·罗氏有限公司 | 抗HER2抗体-药物缀合物和Bcl-2抑制剂的组合疗法 |
| WO2017136603A1 (en) * | 2016-02-02 | 2017-08-10 | Guardant Health, Inc. | Cancer evolution detection and diagnostic |
| CN105524973A (zh) * | 2016-03-15 | 2016-04-27 | 南京华奥生物医药技术有限公司 | 利用自体肿瘤与正常配对原代细胞筛选肿瘤药物的方法 |
| CN107091930B (zh) * | 2017-03-07 | 2020-09-15 | 杭州百凌生物科技有限公司 | 快速预测和提高非小细胞肺癌细胞对表皮细胞生长因子受体抑制剂敏感性的方法 |
| CN107271672B (zh) * | 2017-06-21 | 2019-01-01 | 首都医科大学附属北京友谊医院 | 外泌体p-ERK在制备结直肠癌诊断产品中的应用 |
| KR102094802B1 (ko) * | 2017-10-24 | 2020-03-31 | 고려대학교 산학협력단 | 소변 대사체 분석을 이용한 베체트병의 진단방법 |
| CN111417730A (zh) * | 2017-11-20 | 2020-07-14 | 托雷莫治疗股份公司 | 诊断方法 |
| TWI683905B (zh) * | 2017-11-21 | 2020-02-01 | 長庚醫療財團法人高雄長庚紀念醫院 | 用於檢測川崎氏病的方法及套組以及用於治療川崎氏病的方法 |
| US11976332B2 (en) | 2018-02-14 | 2024-05-07 | Dermtech, Inc. | Gene classifiers and uses thereof in non-melanoma skin cancers |
| KR102199141B1 (ko) | 2019-05-03 | 2021-01-06 | 사회복지법인 삼성생명공익재단 | 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법 |
| EP4185870A1 (en) * | 2020-07-24 | 2023-05-31 | Genentech, Inc. | Determining hemodilution of bone marrow aspirates using biomarkers |
| CN115267165A (zh) * | 2022-08-15 | 2022-11-01 | 海仕兰(上海)生物科技有限公司 | 一种悬浮芯片系统及其应用以及基于悬浮芯片系统对肿瘤伴随诊断因子检测方法 |
| KR20240037082A (ko) * | 2022-09-14 | 2024-03-21 | 아주대학교산학협력단 | 항암제 내성 측정용 바이오 마커 및 이를 이용한 항암제 내성 예측 정보 제공 방법 |
| CN118130793B (zh) * | 2024-02-26 | 2025-07-29 | 赣南医科大学 | 视网膜母细胞瘤的生物标志物cdk12及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6218122B1 (en) * | 1998-06-19 | 2001-04-17 | Rosetta Inpharmatics, Inc. | Methods of monitoring disease states and therapies using gene expression profiles |
| US20060188895A1 (en) * | 2004-08-31 | 2006-08-24 | The Johns Hopkins University | Rapid prognostic assay for malignancies treated with epidermal growth factor receptor |
| US8841076B2 (en) * | 2005-05-09 | 2014-09-23 | Theranos, Inc. | Systems and methods for conducting animal studies |
| WO2006125143A2 (en) * | 2005-05-18 | 2006-11-23 | Novartis Ag | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
| WO2006133399A1 (en) | 2005-06-08 | 2006-12-14 | Hitachi Chemical Research Center, Inc. | METHOD FOR PREDICTING IMMUNE RESPONSE TO NEOPLASTIC DISEASE BASED ON mRNA EXPRESSION PROFILE IN NEOPLASTIC CELLS AND STIMULATED LEUKOCYTES |
| EP1937314A4 (en) | 2005-09-01 | 2009-01-07 | Bristol Myers Squibb Co | BIOMARKERS AND PROCEDURE FOR DETERMINING SENSITIVITY FOR VASCULAR ENDOTHEL GROWTH FACTOR RECEPTOR 2 MODULATORS |
| WO2007143183A2 (en) | 2006-06-04 | 2007-12-13 | Soner Altiok | Methods for developing and assessing therapeutic agents |
| PE20090681A1 (es) * | 2007-03-02 | 2009-06-10 | Genentech Inc | Prediccion de respuesta a un inhibidor her |
| JP2010536371A (ja) * | 2007-08-21 | 2010-12-02 | ノダリティ，インコーポレイテッド | 診断方法、予後および治療方法 |
| EP2210080B1 (en) | 2007-10-24 | 2015-01-28 | Biomarker Strategies, Llc | Improved methods and devices for cellular analysis |
| EP2220503A1 (en) * | 2007-11-30 | 2010-08-25 | Schering Corporation | Braf biomarkers |
-
2011
- 2011-04-18 EP EP11772505.1A patent/EP2561368B1/en active Active
- 2011-04-18 US US13/089,219 patent/US9766249B2/en not_active Expired - Fee Related
- 2011-04-18 ES ES11772505.1T patent/ES2650674T3/es active Active
- 2011-04-18 CN CN201180030332.9A patent/CN102947706B/zh not_active Expired - Fee Related
- 2011-04-18 CN CN201810296066.8A patent/CN108535465A/zh active Pending
- 2011-04-18 CA CA2795362A patent/CA2795362C/en active Active
- 2011-04-18 PL PL11772505T patent/PL2561368T3/pl unknown
- 2011-04-18 JP JP2013506214A patent/JP6158078B2/ja not_active Expired - Fee Related
- 2011-04-18 KR KR1020127029888A patent/KR101977875B1/ko not_active Expired - Fee Related
- 2011-04-18 AU AU2011242990A patent/AU2011242990B2/en not_active Ceased
- 2011-04-18 WO PCT/US2011/032935 patent/WO2011133477A2/en not_active Ceased
- 2011-04-18 SG SG2012074746A patent/SG184507A1/en unknown
-
2016
- 2016-12-16 JP JP2016243869A patent/JP6580546B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-22 HK HK19101066.6A patent/HK1258688A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2561368A4 (en) | 2013-10-09 |
| JP6580546B2 (ja) | 2019-09-25 |
| HK1258688A1 (zh) | 2019-11-15 |
| JP6158078B2 (ja) | 2017-07-05 |
| PL2561368T4 (pl) | 2018-03-30 |
| CN108535465A (zh) | 2018-09-14 |
| EP2561368B1 (en) | 2017-08-02 |
| EP2561368A2 (en) | 2013-02-27 |
| KR101977875B1 (ko) | 2019-05-13 |
| AU2011242990A1 (en) | 2012-11-01 |
| WO2011133477A2 (en) | 2011-10-27 |
| AU2011242990B2 (en) | 2015-02-12 |
| CN102947706B (zh) | 2018-04-13 |
| CA2795362C (en) | 2018-03-20 |
| US9766249B2 (en) | 2017-09-19 |
| WO2011133477A3 (en) | 2012-05-10 |
| JP2017106923A (ja) | 2017-06-15 |
| CA2795362A1 (en) | 2012-10-02 |
| JP2013525786A (ja) | 2013-06-20 |
| SG184507A1 (en) | 2012-11-29 |
| US20120094853A1 (en) | 2012-04-19 |
| ES2650674T3 (es) | 2018-01-19 |
| CN102947706A (zh) | 2013-02-27 |
| KR20130095183A (ko) | 2013-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2561368T3 (pl) | Kompozycje i sposoby do przewidywania wrażliwości i oporności na lek oraz progresji choroby | |
| IL250824B (en) | Certain amino-pyrimidines, their assemblies, and methods of using them | |
| HRP20181320T8 (hr) | Ljudska anti-tau protutijela | |
| EP2585583A4 (en) | CELLULAR CONSTITUENTS FROM BACTEROID GENE BACTERIA, COMPOSITIONS CONTAINING SAME, AND THERAPEUTIC METHODS USING BACTEROID BACTERIA OR CELLULAR COMPONENTS THEREOF | |
| IL222738A0 (en) | Pharmaceutical emulsion composition comprising progestogen | |
| EP2521553A4 (en) | METHODS AND COMPOSITIONS FOR THE DEVELOPMENT OF TARGETED MEDICAMENTS | |
| IL226106A0 (en) | Methods and preparations for immunotherapy in neurological diseases | |
| HUE044521T2 (hu) | Görögdinnye szilárdságával kapcsolatos eljárások és kompozíciók | |
| BR112012000831A2 (pt) | compostos, composições farmacêuticas e métodos relacionados | |
| HUE053623T2 (hu) | Vegyületek és azok felhasználása | |
| GB201017597D0 (en) | Drug detection | |
| EP2852570A4 (en) | Compositions and methods for the treatment of inflammatory bowel disease | |
| SMT201500005B (it) | Composizione framaceutica inalabile | |
| ZA201306905B (en) | Novel octahydrothienoquinonline derivative,pharmaceutical composition comprising derivative, and use of these | |
| EP2543388A4 (en) | MEDICINAL PRODUCT FOR INFLAMMATORY ENDURANCE | |
| HUE053664T2 (hu) | Eljárások és készítmények Polyomavírussal összefüggõ betegségek gátlására | |
| EP2626347A4 (en) | DALFAMPRIDINPOLYMORPH AND THE PREPARATION AND USE THEREOF | |
| IT1403289B1 (it) | Metallo alchil-areni e procedimenti per la loro preparazione | |
| GB201005905D0 (en) | Disease determination | |
| AU2010900589A0 (en) | Super health drug | |
| AU2010900588A0 (en) | Super health drug | |
| EP2730283A4 (en) | PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES, ALLERGIC DISEASES AND AUTOIMMUNE DISEASES | |
| TWM402053U (en) | Dry-wet-separated instant noodle bowl | |
| IL226635B (en) | Human anti-sod1 antibodies | |
| GB201003342D0 (en) | Manufacture of insoluble drugs |